Although the central role of 1p/19q codeletion in oligodendroglioma was established almost two decades ago, apart from clear prognostic significance the implications for clinical care have been less clear. This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma. These have shown that 1p/19q loss in these tumors is predictive of overall survival benefit of the addition of PCV chemotherapy to radiotherapy.

dx.doi.org/10.1200/EdBook_AM.2013.33.114, hdl.handle.net/1765/82164
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Department of Medical Oncology

van den Bent, M.J. (2013). How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 114–116. doi:10.1200/EdBook_AM.2013.33.114